257 results about "Transport protein" patented technology

The invention belongs to the technical field of gene engineering, and particularly relates to a mutant of polymyxin efflux transporter and application of the mutant. The mutant is a PmxD transporter mutant, the amino acid sequence of the PmxD transporter mutant is shown as SEQ ID NO: 1, and compared with wild type PmxD, the polymyxin transport capacity of the PmxD transporter mutant (T38W) is improved by 450.46%; and the total discharge amount of polymyxin is increased by 85.72%. Meanwhile, the mutant can significantly improve the growth ability of the strain on a plate containing 250 [mu] g / mL of polymyxin B, namely significantly improve the autoresistance of paenibacillus polymyxa to polymyxin.

The invention belongs to the technical field of biology, and discloses application of a lignin monomer transporter. The amino acid sequence of the lignin monomer transporter is as shown in SEQ ID No: 1. The application is used for constructing a recombinant strain growing in a culture medium of lignin-derived aromatic compounds, or used for constructing a recombinant strain for producing microbial proteins and / or lipids. According to the novel lignin monomer transport protein driven by deep learning, the metabolic bottleneck of lignin utilization is broken through, the key protein transported by the lignin monomer is excavated, the lignin monomer transport capacity can be endowed to a microbial chassis, and a multifunctional microbial platform is provided for sustainable biological refining.

Described herein are compositions and methods for treatment of Age-related Macular Degeneration (AMD). In particular, described herein are polypeptides comprising helical structures having ATP binding cassette transporter membrane stabilization and agonist activity, transporter protein binding activity, and / or that may result in a cholesterol efflux, as well as methods of using these peptides to treat AMD.

The invention discloses a cherry sugar transporter gene CpSWEET10 and application thereof, and belongs to the technical field of cherry gene engineering. A novel sugar transporter gene CpSWEET10 is obtained through cloning, the nucleotide sequence of the novel sugar transporter gene CpSWEET10 is shown as SEQ ID NO.1, and the coded amino acid sequence of the novel sugar transporter gene CpSWEET10 is shown as SEQ ID NO.2. The gene is highly expressed in cherry fruits, and the content of soluble solids and total sugar in mature fruits is remarkably positively correlated with the expression quantity of the soluble solids and the total sugar; through subcellular localization and sugar transport function defect type yeast mutant functional complementation experimental analysis, the protein coded by the CpSWEET10 gene is localized in a cytoplasmic membrane and has a sucrose transport function; the cherry sugar transporter gene CpSWEET10 disclosed by the invention can be applied to the improvement of the sugar degree character of the fruits, and a new gene resource is provided for molecular breeding for improving the high-sugar quality of the cherry fruits.

The invention provides an application of a citrus transcription factor CsAGL9 gene and a protein coded by the citrus transcription factor CsAGL9 gene in regulating and controlling the content of citric acid in citrus fruits, the nucleotide sequence of the CsAGL9 gene is shown as SEQ ID NO.1, and the amino acid sequence of the protein is shown as SEQ ID NO.2. The content of citric acid in the fruits can be reduced through overexpression in the oranges; the content of citric acid in fruits can be increased by silencing the gene. It is further verified that the gene promotes the activity of the citrus citric acid transporter CsTCT1. The discovery provides a new gene resource for citrus quality improvement and molecular design breeding, and provides an efficient tool for fruit quality improvement.

The invention provides a milk protein peptide which takes milk protein as a raw material and has the effects of promoting calcium absorption and improving bone health and application of the milk protein peptide. Specifically, milk protein peptide sequences, including YGGVSL and SQRY, are screened by adopting enzymolysis, sequence identification and molecular docking methods. The milk protein peptide is proved to have high calcium transport promoting capacity in the in-vitro intervention of Caco-2 cells, and the milk protein peptide is proved to have the capacity of promoting osteogenesis and inhibiting bone resorption in the in-vitro intervention of MC3T3-E1 mouse embryo osteoblasts. In animal experiments, by increasing the content of blood calcium and bone calcium, reducing the content of excrement calcium, improving mRNA expression of calcium ion channel protein, calcium binding protein and peptide transporter in intestinal tracts, enhancing the efficiency of calcium entering blood, promoting osteogenesis and inhibiting bone resorption, the milk protein peptide is comprehensively proved to have the capabilities of improving calcium resorption of organisms and improving bone health. The milk protein peptide has both functionality and nutrition, and has a wide application prospect in the aspect of bone health.

The invention provides an application of a peach transport protein PpSWEET11 in regulating and controlling the hexose content of fruits. According to the invention, the function of the PpSWEET11 gene is cloned and verified, and through overexpression of the PpSWEET11 in peach fruits and tomatoes, the glucose and fructose levels in an overexpression group are obviously increased compared with those in a control group, which indicates that the PpSWEET11 has a wide sugar transport function. The invention not only expounds the effect of the PpSWEET11 in the aspect of sugar accumulation and provides a key molecular insight in the aspect of improving sugar accumulation of peaches and other economically important fruit crops, but also can be applied to nutritional quality improvement and germplasm innovation of peach fruits.

The invention belongs to the technical field of genetic engineering, and relates to the field of wheat genetic engineering, in particular to a gene TaABCG42 for regulating and controlling cadmium accumulation of wheat as well as an encoding protein and application of the gene TaABCG42. According to the invention, a TaABCG42 gene is knocked out by using CRISPR / Cas9, a TaABCG42 gene overexpression plant is constructed at the same time, and a homozygous mutant is obtained by using a Hi-Tom sequencing technology and PCR (Polymerase Chain Reaction) successive generation screening. A wild type TaABCG42 homozygous overexpression and knockout plant treated with a 40 [mu] mol / L Cd solution for 5 days is subjected to analysis such as metal content determination, subcellular component metal determination, Cd chemical form determination and Cd ion flow determination, and the Cd absorption and transport approach of TaABCG42 is analyzed, so that the physiological and molecular mechanism of the TaABCG42 metal transporter for absorbing and transporting Cd is explored, and the application prospect is wide. The understanding on the wheat ABC metal transporter is enriched, and a theoretical basis is provided for cultivating high-quality wheat with low Cd accumulation.

The invention discloses a tomato Solyc08g008190 gene and a tomato Solyc08g008200 gene and application of the tomato Solyc08g008190 gene and the tomato Solyc08g008200 gene. A CDS (Coding Sequence) sequence of the Solyc08g008190 gene is shown as SEQ ID NO. 1, and a CDS sequence of the Solyc08g008200 gene is shown as SEQ ID NO. 2. A tomato transporter mutant library is constructed through a CRISPR (clustered regularly interspaced short palindromic repeats) technology, and a mutant 0990-32 which simultaneously covers expression of two homologous genes of an NHE family is screened. Based on observation of the phenotype of the mutant, the inventor preliminarily determines that the two genes are related to tomato fruit quality and fruit volume increase. Compared with a wild type, the tomato fruit of the mutant has the advantages that the brix content is increased, and the fruit becomes larger. It is shown that the Solyc08g008190 gene and the Solyc08g008200 gene play an important role in regulating and controlling the growth, development and quality of the tomato fruits. The invention lays a good gene genetic resource foundation for the cultivation of new varieties of high-quality tomatoes.

The invention belongs to the technical field of biological medicine, and relates to application of a clerodendranthus spicatus tea bag in regulating intestinal excretion and reducing uric acid. One of the purposes of the invention is to provide the application of the clerodendranthus spicatus teabag in regulating intestinal tracts to reduce uric acid According to a preferred embodiment, the clerodendranthus spicatus teabag regulates ATP binding cassette transporter G2 and inhibits uricase activity. The invention provides the application of the clerodendranthus spicatus teabag in regulating the intestinal microbial environment and reducing uric acid, and the clerodendranthus spicatus teabag has remarkable beneficial effects. The clerodendranthus spicatus teabag can effectively regulate the structure and the function of intestinal microflora, especially the enrichment amount of characteristic bacteria Muriaculum in the intestinal tract, further strengthens the probiotic activity of the intestinal flora, and is helpful for maintaining the steady state of uric acid in the body. The multi-way synergistic effect not only provides an innovative strategy for preventing and treating hyperuricemia and related metabolic diseases, but also avoids side effects possibly brought by traditional medicines, and shows good application prospects and clinical values.

Methods of treating age-related macular degeneration (AMD) may include the administration of amphipathic, ATP binding cassette transporter membrane agonists to reduce the amount of drusen in the subject in need thereof. These methods may be particularly useful for treatment of intermediate AMD.

The invention relates to the field of synthetic biology, metabolic engineering and fermentation engineering, and discloses a genetically engineered bacterium and application thereof in production of alpha-ketoglutaric acid.The genetically engineered bacterium comprises the steps that the genetically engineered strain with escherichia coli BW25113 or corynebacterium glutamicum ATCC13032 as a host is constructed; overexpression type isocitrate dehydrogenase genes are integrated through chromosomes, alpha-ketoglutarate dehydrogenase complex genes are knocked out, NADPH invertase is overexpressed through plasmids, and exogenous AKG transporter protein is introduced, so that metabolic flux directional regulation and control and product efflux enhancement are realized; meanwhile, a staged fermentation process is adopted and comprises dynamic gradient adjustment of inorganic phosphorus concentration and two-stage pH control. According to the method, the AKG yield of 78.2 g / L can be obtained under the 5L tank scale, the sugar acid conversion rate reaches 0.68, and the method has the advantages of being high in yield, low in byproduct and controllable in cost. The obtained AKG is suitable for a plurality of fields such as medical intermediates, functional foods and cell culture additives, and has wide industrial application prospects.

The invention discloses a genetically engineered bacterium and an application of the genetically engineered bacterium in production of farnesene. The genetically engineered bacterium takes saccharomyces cerevisiae as a chassis strain; an exogenous beta-farnesene synthase gene is integrated, an ERG9 gene is knocked out, a promoter of a truncated HMG1 gene is replaced with an ANB1 promoter, an exogenous transhydrogenase gene is integrated and driven by a glucose sensitive promoter, beta-farnesene synthase is mutated and fused with a transmembrane structural domain of ABC transporter protein PDR10, and then a chimeric expression unit is constructed. According to the present invention, the chassis bacteria are modified by at least one of the steps of overexpression of phosphatidylcholine synthetase, knockout of sterol ester synthetase and introduction of exogenous alkyl glycerol monooxygenase, and the obtained engineering bacteria are combined with the optimized fermentation process so as to significantly improve the farnesene synthesis efficiency and the production economy; therefore, the genetically engineered bacterium and the fermentation method provided by the invention have good application prospects.

This invention relates to a method for producing chondroitin with improved safety and extracellular secretion levels, belonging to the field of genetic engineering. Using the probiotic *Escherichia coli* Nissle 1917 as the host, this invention designs methods to increase chondroitin production by studying the chondroitin synthase KfoAC and the chondroitin-linking Kdo synthase. The relationship between chondroitin synthesis and secretion in *E. coli* was clarified, and the specificity of the chondroitin-linking Kdo was investigated, resulting in an extracellular chondroitin production of 0.32 g / L. Subsequently, the introduction of the protein KfoB from the chondroitin synthesis gene cluster increased the extracellular chondroitin production to 0.51 g / L. Further screening and optimization of the expression of transport proteins resulted in an extracellular chondroitin production of 0.73 g / L in shake flasks. Further optimization using a 7-L fermenter resulted in an extracellular chondroitin production of 5.9 g / L.

Provided herein is a method of administering levoketoconazole, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered a multidrug and toxin extrusion transporter 1 (MATE1) substrate or an organic cation transporter 2 (OCT2) substrate.

One aspect of the present invention relates to: a conjugate comprising a peptide of a novel sequence and glycyrrhizin; and a pharmaceutical composition for preventing or treating obesity, the composition comprising the conjugate. The conjugate and composition comprising same according to one aspect were found to inhibit hypertrophy of fat cells, increase the cell membrane expression level of ATP-binding cassette transporter A1 (ABCA1), and reduce the secretion of tumor necrosis factor-α (TNF-α). In addition, the conjugate and composition comprising same were found to remain in a greater amount in the blood and have better pharmacokinetic properties than glycyrrhizin used by itself, and thus can be used in the obesity prevention and / or treatment market / industry.

The invention discloses a method for constructing a high-yield natamycin engineering strain through overexpression of an extracellular transport protein gene pimA and a pathway specific regulation gene pimR, and the high-yield engineering strain is applied to fermentation production of natamycin. The yield of the natamycin can reach 19.49 g / L through fed-batch fermentation in a fermentation tank of 5L of the high-yield strain S.ilvosporeus pimA-pimR, and the yield of the natamycin is improved by 33.12% compared with the yield of a chassis strain S.ilvosporeus TUST01; the production intensity is improved by 33.33% compared with the production intensity of a chassis strain S.ilvosporeus TUST01, and the strain has a relatively high industrial application value.

The invention relates to the technical field of biology, in particular to engineered yeast for high-yield citronellol as well as a preparation method and application of the engineered yeast. According to the invention, genetically engineered bacteria for high yield of citronellol are constructed by means of genetic engineering, SyBESc081300004 is taken as an original strain, Erg20ww, Erg8, tCrGES and CrIS are expressed in a peroxisome region in a room manner, and phosphopentose pathway genes TAL1 and TKL1 and endogenous transporter protein PDR1 are over-expressed, so that the genetically engineered bacteria are obtained; experimental results show that the shake flask fermentation yield of the genetically engineered bacterium reaches 3.38 g / L, the yield of a 100L fermentation tank reaches 10.556 g / L, and the yield of the genetically engineered bacterium is obviously higher than that of other existing citronellol production engineered bacterium.

The application discloses a method for promoting transport and improving retinal synthesis, which is obtained by introducing an exogenous ABC transport protein Pdr5 into a host fungus and adding a copy of beta-carotene-15, 15'-monooxygenase BLH; wherein the host fungus is a genetically modified Pichia pastoris strain PP-BCCIV. The application further verifies the retinal production performance of the recombinant strain by screening different surfactants, and further improves the ability of Pichia pastoris to produce retinal. At the same time, all the retinal is extracted into the extracellular, and all the carotenes are left in the intracellular, so as to achieve the co-production of carotenes and retinal. The recombinant Pichia pastoris of the application has a simple construction method, can better promote the synthesis of retinal and other vitamin A, and can make the engineering strain utilize glucose and methanol to efficiently synthesize retinal through a 5 L fermentation tank, which is beneficial to industrial production.

Provided are a recombinant Escherichia coli with improved ability to secrete extracellular endoglucanase (BcsZ) and a construction method therefor. The recombinant Escherichia coli is constructed by using Escherichia coli JBZ-DH5α as a starting strain and inserting a membrane protein coding gene. The membrane protein gene is one of the following coding genes: a coding gene of zinc transporter permease znuB, a coding gene of DUF1449 family inner membrane protein ylaC, and a coding gene of UPF0410 family inner membrane protein ymgE.

The invention discloses a pugionium cornutum cation-Cl-co-transporter protein coding gene PcCCC1 and application thereof. The nucleotide sequence of the cation-Cl-co-transporter protein coding gene PcCCC1 is as shown in SEQ ID No.1, the amino acid sequence of the coding protein of the cation-Cl-co-transporter protein coding gene PcCCC1 is as shown in SEQ ID No.2, and the sequence of a specific promoter of the cation-Cl-co-transporter protein coding gene PcCCC1 is as shown in SEQ ID No.3. The invention further discloses an application of the cation-Cl-co-transporter protein coding gene PcCCC1. Experiments prove that after the gene is driven by a specific promoter of the gene to be overexpressed in arabidopsis thaliana, accumulation of Na < + > and Cl <-> of the overground part under salt stress can be reduced, so that the salt tolerance of the plant is improved, a gene resource is provided for improvement of the salt tolerance of the plant, and the gene has a wide application value.

The invention relates to the technical field of preparation of deep-sea longevity fish precise active peptides, in particular to a deep-sea longevity fish precise active peptide with uric acid reducing and anti-inflammatory effects as well as a preparation method and application of the deep-sea longevity fish precise active peptide. The preparation method comprises the following steps: carrying out medium-temperature pretreatment, carrying out step-by-step enzymolysis with alkaline protease and acid protease, centrifuging, filtering, carrying out ultrafiltration interception and the like, and screening out 10 non-reported non-toxic active peptide fragments. The active peptide has a multi-target synergistic effect, inhibits the activity of xanthine oxidase, regulates and controls the expression of uric acid resorption protein, regulates and controls the expression of uric acid transporter protein, realizes bidirectional regulation of uric acid metabolism, efficiently removes hydroxyl radicals, activates superoxide dismutase and reduces the content of inflammation-related factors. The technology is simple and easy to control, low in equipment requirement and suitable for large-scale production, the active ingredients are natural, safety is high, the active ingredients can serve as functional factors to be applied to functional food, health care products and the like, and safe and diversified intervention schemes are provided for hyperuricemia and related inflammation problems.

The invention relates to the technical field of gene engineering, and discloses a recombinant strain, a construction method and application thereof, and a method for producing total fatty acid. The recombinant strain is obtained by genetic modification of an original strain, and compared with the original strain, the recombinant strain overexpresses citric acid transporter Yhm2p, cis-aconitase E.HA and isocitrate dehydrogenase IDP located in cytoplasm at the same time, and does not express isocitrate dehydrogenase IDH1 and isocitrate dehydrogenase IDH2 located in mitochondria. The recombinant strain provided by the invention forms a high-efficiency pathway of citric acid retention-cytoplasm transport-directional production of NADPH, so that the core bottleneck of insufficient supply of cytoplasm NADPH in fatty acid synthesis is solved, the total fatty acid yield is remarkably increased, the transformation logic is accurate, and a stable and reliable source is provided for industrial high-efficiency production of fatty acid.

The invention relates to the technical field of polypeptide compositions, and discloses a silkworm-derived protein peptide with blood sugar regulation and immune function activity and an application method, the silkworm-derived protein peptide comprises a silkworm-derived acidic active peptide group, a silkworm-derived alkaline daemon peptide group, a divalent cation coordination center and a silkworm-derived proline enriched peptide group; the silkworm source acidic active peptide group and the silkworm source alkaline daemon peptide group are mixed according to the mass ratio of (3: 1)-(5: 1), and an electrically neutral nano peptide cluster with the average particle size smaller than 100 nm is formed through electrostatic complexation; the silkworm-derived alkaline daemon peptide group contains histidine residues, imidazolyl of the silkworm-derived alkaline daemon peptide group is protonated in an acid environment to generate charge repulsive force, electrostatic repulsive force generated when active peptide penetrates through intestinal epithelial cell membranes is eliminated by utilizing a component charge counteracting mechanism, the apparent treatment flux of transporter protein on core components is enhanced, and the biological activity of the silkworm-derived alkaline daemon peptide group is improved. And intracellular dissociation of the peptide cluster is triggered by virtue of a protonation induction lock, so that accurate resetting of an active site at a target spot is ensured, and the technical problems that transmembrane absorption of the high-activity polar peptide is limited and intracellular release is delayed are solved.

The present invention discloses a recombinant antigen protein SecG of Helicobacter pylori and its preparation method and application. The amino acid sequence of the recombinant antigen protein SecG is shown in SEQ ID NO: 1, and the nucleotide sequence of the recombinant antigen protein SecG encoding gene is shown in SEQ ID NO: 2. The present invention obtains a high-purity antigen protein through the steps of plasmid construction, induced expression, affinity chromatography and exchange chromatography purification. The purification process is simple, low in cost, and highly operable. The antigen prepared after purification has high immunogenicity and immune titer and can be used as a genetically engineered subunit vaccine. As an important component protein in the membrane transport protein of Helicobacter pylori, the antigen protein SceG will become one of the most promising candidate antigens in the development of Helicobacter pylori genetically engineered vaccines.

The invention discloses a genetically engineered bacterium for synthesizing L-glutamine by taking glucose as a carbon source and application of the genetically engineered bacterium. The genetically engineered bacterium takes escherichia coli as a chassis strain; according to the invention, a citrate synthase gene gltA, an aconitic acid hydratase gene can, an isocitrate dehydrogenase gene icd, a glutamate dehydrogenase gene gdh, a glutamine synthetase gene glnA and ammonium transporter genes amt and amtb can be overexpressed. Compared with the prior art, the invention provides a new strain and a new method for biosynthesizing L-glutamine, and the new strain and the new method have the significances of economy, scientificity, low cost, simple process and large-scale production.

The present invention relates to a novel PTS transporter subunit EIIC variant and a method of producing 5′-inosinic acid using the same. The PTS transporter subunit EIIC variant is obtained by substituting one or more amino acids in the amino acid sequence constituting PTS transporter subunit EIIC to change the activity of the protein, and a recombinant microorganism comprising the PTS transporter subunit EIIC variant is capable of efficiently producing 5′-inosinic acid.

This invention relates to the field of biosynthesis technology, and particularly to engineered yeast strains and their application in the total fermentation production of steviol glycosides. This invention utilizes site-directed mutagenesis to mutate wild-type kaurenoic acid 13-hydroxylase, obtaining the G481L / Q159L mutant. This mutant is then applied to the production of steviol or steviol glycosides, constructing a steviol or steviol glycoside synthesis pathway in the *Saccharomyces cerevisiae* host to achieve efficient production of steviol or steviol glycosides. Simultaneously, by enhancing the level of diterpene precursor synthesis genes in chassis cells (MVA pathway, acetyl-CoA, GGPP, transport proteins, UDPG pathway), the yield of steviol glycosides is further increased, reducing costs for industrial production.

The invention relates to a PKM2-based nano glycopeptide activator and application thereof.The nano glycopeptide activator comprises three functional units, namely a PKM2 targeted activation unit R3, a self-assembly unit R2 and a response unit R1, and the chemical structure of the nano glycopeptide activator is shown in the formula (I). After administration, the nano glycopeptide activator can be enriched to a tumor site through targeting of sugar receptor transporter protein or an EPR effect; after entering tumor cells, the polypeptide is subjected to in-situ fibrosis deformation under the hydrolysis action of glycohydrolase, so that specific targeting and retention are realized; the nano-fiber with the PKM2 targeting activation unit can promote conversion of dimer PKM2 into tetramer PKM2, inhibit nucleation of PKM2, and prevent the DNA damage repair process of tumor cells.

The invention discloses an ingenol ABC transport protein ElABCG39 as well as a coding gene and application thereof. The protein is positioned in a cytoplasmic membrane, and expression of the protein in yeast proves that the protein has ingenol transmembrane efflux transport function, improves the ingenol tolerance of the yeast, and proves that the ElABCG39 has certain substrate specificity in the yeast. The ingenol ABC transporter ElABCG39 can be used for producing ingenol by fermentation of microorganisms or plant tissues.